News
Sanofi, Regeneron’s wager on Dupixent in COPD pays off
Sanofi and Regeneron acknowledged that testing their inflammatory disease blockbuster Dupixent in chronic obstructive pulmonary disease (COPD) was likely to be high-risk w
